Impact of study design and patient population on outcomes from cholinesterase inhibitor trials

American Journal of Geriatric Psychiatry

Volumn 11, Issue 2, 2003, Pages 160-168

  Anand, Ravi ^e   Hartman, Richard ^a   Sohn, Hyesung ^b   Danyluk, Jacquiline ^c   Graham, Stephen M ^d  

^a Ingenix   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Med Scriptor Inc   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED RELEASE FORMULATION; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; META ANALYSIS; NAUSEA; OUTCOMES RESEARCH; PATIENT SELECTION; VERTIGO; VOMITING;

EID: 0344089320     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200303000-00006     Document Type: Article

References (34)

1. Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, part I. J Clin Psychiatry 2000; 61:710-711
2. Knapp MJ, Knopman DS, Solomon PR, et al: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985-991
3. Farlow M, Gracon SI, Hershey LA, et al: A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-2529
4. Rogers SL, Doody RS, Mohs RC, et al: Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 1998; 158:1021-1031
5. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145
6. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a U.S. multicentre open-label extension study. Eur Neuropsychopharmacol 1998; 8:67-75
7. Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology 1998; 1:55-65
8. Rösler M, Anand R, Cicin-Sain A, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999; 318:633-640
9. Vellas B, Inglis E Potkin S, et al: Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild-to-severe Alzheimer's disease patients. International Journal of Geriatric Psychopharmacology 1998; 1:140-144
10. Tariot PN, Solomon PR, Morris JC, et al: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54:2269-2276
11. Raskind MA, Peskind ER, Wessel T, et al: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54:2261-2268
12. Wilcock GK, Lilienfeld S, Gaens E, et al: Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicentre randomized controlled trial. BMJ 2000; 321:1445-1449
13. Thal LJ, Schwartz G, Sano M, et al: A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996; 47:1389-1395
14. Thal LJ, Ferguson JM, Mintzer J, et al: A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 1999; 52:1146-1152
15. Becker RE, Culliver JA, Markwell SJ, et al: Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 1996; 10:124-131
16. Cummings JL, Cyrus PA, Bieber E et al: Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998; 50:1214-1221
17. Morris JC, Cyrus PA, Orazem J, et al: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50:1222-1230
18. Raskind MA, Cyrus PA, Ruzicka BB, et al: The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. J Clin Psychiatry 1999; 60:318-325
19. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Press, 1994
20. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group Under the Auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
21. Folstein MF, Folstein SF, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
22. Novartis Pharmaceuticals Corporation, data on file
23. Aricept® U.S. Package Insert. New York, Roerig, Division of Pfizer, Inc., 1996
24. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
25. Kramer-Ginsberg E, Mohs RC, Aryan M, et al: Clinical predictors of course for Alzheimer's patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988; 24:458-462
26. Stern RG, Mohs RC, Davidson M, et al: A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151:390-396
27. Mendiondo MS, Wesson AJ, Kryscio RJ, et al: Modeling Mini-Mental State Exam changes in Alzheimer's disease. Stat Med 2000; 19:1607-1616
28. Migranal® U.S. Package Insert, East Hanover, NJ, Novartis Pharmaceuticals Corporation, 1998
29. Moher D, Schulz KF, Altman D, et al: The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials. JAMA 2001; 285:1987-1991
30. Guyatt GH, Sackett DL, Cook DJ, et al: Users' guides to the medical literature, II: how to use an article about therapy or prevention, A: are the results of the study valid? JAMA 1993; 270:2598-2601
31. Guyatt GH, Sackett DL, Cook DJ, et al: Users' guides to the medical literature, II: how to use an article about therapy or prevention, B: what were the results and will they help me in caring for my patients? JAMA 1994; 271:59-63
32. Farlow M, Anand R, Messina Jr J, et al: A 52-week study of the efficacy of rivastigmine in patients with mild-to-moderately severe Alzheimer's disease. Eur Neurol 2000; 44:236-241
33. Physicians' Desk Reference, 2001
34. Cognex® U.S. Package Insert, Morris Plains, NJ, Warner-Lambert Division, 1999